Syros Pharmaceuticals Inc (NAS:SYRS)

$ 1.5675 -0.035 (-2.18%) Market Cap: 42.02 Mil Enterprise Value: 24.59 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 38/100

Q1 2024 Syros Pharmaceuticals Inc Earnings Call Transcript
May 14, 2024

$5.43 (+7.31%)

Earnings
Q4 2023 Syros Pharmaceuticals Inc Earnings Call Transcript
Mar 27, 2024

$5.84 (-6.56%)

Earnings
Syros Pharmaceuticals Inc Conference Call Transcript
Dec 06, 2023
Q3 2023 Syros Pharmaceuticals Inc Earnings Call Transcript
Nov 14, 2023

$2.72 (+1.12%)

Earnings
Q2 2023 Syros Pharmaceuticals Inc Earnings Call Transcript
Aug 08, 2023

$3.66 (-0.54%)

Earnings
Syros Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 01, 2023
Syros Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript
May 16, 2023
Q1 2023 Syros Pharmaceuticals Inc Earnings Call Transcript
May 10, 2023

$3.43 (+10.29%)

Earnings
Q4 2022 Syros Pharmaceuticals Inc Earnings Call Transcript
Mar 02, 2023

$3.76 (+2.73%)

Earnings
Syros Pharmaceuticals Inc to Discuss Ongoing Phase 2 SELECT-AML-1 Clinical Trial Transcript
Dec 10, 2022
Q3 2022 Syros Pharmaceuticals Inc Earnings Call Transcript
Nov 14, 2022

$3.66 (-8.04%)

Earnings
Q2 2022 Syros Pharmaceuticals Inc Earnings Call Transcript
Aug 09, 2022

$9.27 (-4.90%)

Earnings
Syros Pharmaceuticals Inc to Acquire TYME Technologies Inc Call Transcript
Jul 05, 2022
Syros Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript
Jun 15, 2022
Q1 2022 Syros Pharmaceuticals Inc Earnings Call Transcript
May 16, 2022

$7.7 (-14.38%)

Earnings
Q4 2021 Syros Pharmaceuticals Inc Earnings Call Transcript
Mar 15, 2022

$11.1 (+3.74%)

Earnings
Q3 2021 Syros Pharmaceuticals Inc Earnings Call Transcript
Nov 05, 2021

$45.6 (+3.17%)

Earnings
Syros Pharmaceuticals Inc at ESMO Congress Conference Call Transcript
Sep 20, 2021
Q2 2021 Syros Pharmaceuticals Inc Earnings Call Transcript
Aug 05, 2021

$49 (+8.65%)

Earnings
Syros Pharmaceuticals Inc SY-2101 in APL-Call Transcript
Jul 20, 2021
Syros Pharmaceuticals Inc SY-1425 in Newly Diagnosed Unfit AML-Call Transcript
Jun 22, 2021
Syros Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 08, 2021
Syros Pharmaceuticals Inc SY-1425 in Newly Diagnosed HR-MDS - Corporate Call Transcript
May 26, 2021
Q1 2021 Syros Pharmaceuticals Inc Earnings Call Transcript
May 06, 2021

$55.3 (+0.91%)

Earnings
Syros Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 16, 2021
Q4 2020 Syros Pharmaceuticals Inc Earnings Call Transcript
Mar 04, 2021

$79.6 (-4.33%)

Earnings
Syros Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Syros Pharmaceuticals Inc New Data From Phase 2 Clinical Trial of SY-1425 and Plans to Initiate Registration-Enabling Trial in MDS and Randomized Phase 2 Trial in AML Call Transcript
Dec 05, 2020
Q3 2020 Syros Pharmaceuticals Inc Earnings Call Transcript
Nov 05, 2020

$81.1 (-1.82%)

Earnings
Q2 2020 Syros Pharmaceuticals Inc Earnings Call Transcript
Aug 06, 2020

$120.3 (+6.65%)

Earnings
Q1 2020 Syros Pharmaceuticals Inc Earnings Call Transcript
May 07, 2020

$87.7 (-3.63%)

Earnings
Q4 2019 Syros Pharmaceuticals Inc Earnings Call Transcript
Mar 05, 2020

$60.2 (-3.68%)

Earnings
Q3 2019 Syros Pharmaceuticals Inc Earnings Call Transcript
Nov 12, 2019

$50.2 (+0.60%)

Earnings
Syros Pharmaceuticals Inc to Announce Update on Selective CDK7 Inhibitor Portfolio Call Transcript
Oct 17, 2019
Q2 2019 Syros Pharmaceuticals Inc Earnings Call Transcript
Aug 01, 2019

$84.8 (+13.37%)

Earnings
Q1 2019 Syros Pharmaceuticals Inc Earnings Call Transcript
May 01, 2019

$71.7 (-0.83%)

Earnings
Q4 2018 Syros Pharmaceuticals Inc Earnings Call Transcript
Mar 07, 2019

$69 (-2.40%)

Earnings

Syros Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 16, 2021 / 12:40PM GMT

Release Date Price: $92.45 (-1.75%)

Transcript

Mark Alan Breidenbach

Oppenheimer & Co. Inc., Research Division - Executive Director & Senior Analyst

Welcome to Oppenheimer's 31st Annual Healthcare Conference. My name is Mark Breidenbach. I'm part of the biotech equity research team. Our next presenting company is Syros, which is developing small molecule therapies for cancer and rare disease, and I'm delighted to introduce the company's CFO, Joe Ferra, who is going to walk us through the story this morning. Joe, why don't you take it away.

Joseph J. Ferra

Syros Pharmaceuticals, Inc. - CFO & Treasurer

Thank you, Mark. I appreciate it, and thank you, everyone, for joining us today. And a big thank you to the Oppenheimer team for giving us an opportunity to present. As Mark mentioned, I'm the CFO of Syros. During this presentation, I will be making some forward-looking statements. For a complete review of our risk factors, I invite you to visit our website at www.syros.com. While you are there, please be sure to check out the blog

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.